Marshall Wace’s ArriVent BioPharma AVBP Stock Holding History

Marshall Wace’s Portfolio AVBP Stock Details AVBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$811K	Sell	35,165 -63,819	-64%	-$1.44M	﹤0.01%	2227
2025 Q4	$1.99M	Sell	98,984 -81,239	-45%	-$1.69M	﹤0.01%	1589
2025 Q3	$3.33M	Buy	+180,223	New	+$3.54M	﹤0.01%	1372
2025 Q2	–	Sell	-35,851	Closed	-$663K	–	3265
2025 Q1	$663K	Buy	+35,851	New	+$877K	﹤0.01%	1950
2024 Q4	–	Sell	-85,250	Closed	-$2M	–	3073
2024 Q3	$2M	Buy	+85,250	New	+$1.94M	﹤0.01%	1366

Other funds holding AVBP

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace's AVBP Position: Q1 2026 in Review

Marshall Wace reduced its ArriVent BioPharma (AVBP) stake by 64% in Q1 2026, selling an estimated $1.44M and leaving 35,165 shares worth $811K. The position accounts for ﹤0.01% of the portfolio, ranked #2227.

Marshall Wace first reported a position in AVBP in Q3 2024 and has held it in 5 quarters since. The position peaked at $3.33M in Q3 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

Marshall Wace held 35,165 shares of ArriVent BioPharma worth $811K as of Q1 2026.
Marshall Wace sold 63,819 ArriVent BioPharma shares in Q1 2026, an estimated $1.44M.
ArriVent BioPharma made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2227 holding.
Marshall Wace first reported a position in ArriVent BioPharma in Q3 2024 and has held it in 5 quarters since.
Marshall Wace's ArriVent BioPharma position peaked at $3.33M in Q3 2025.
139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.